Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A live Pharma & Life Sciences Clinical and Evidence Strategy file in a safety team sitting on a new disproportionate signal now turns on scientific-advice briefing book after a competitor label that just got a narrower indication. CMC change-control owner should state what that extract proves for whether to drop a secondary endpoint that will dominate the AdCom.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; scientific-advice briefing book already has the discriminator after a competitor label that just got a narrower indication. 2. Keep Pause the pathway in force until scientific-advice briefing book is completed after a competitor label that just got a narrower indication for CMC change-control owner. 3. Treat scientific-advice briefing book as Escalate safety review because both readings appear after a competitor label that just got a narrower indication. 4. Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the decision to drop a secondary turns on in scientific-advice briefing book.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether scientific-advice briefing book supports the labeled claim CMC change-control owner would keep. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read scientific-advice briefing book against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (scientific-advice briefing book after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option scientific-advice briefing book can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for CMC change-control owner in a safety team sitting on a new disproportionate signal.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in scientific-advice briefing book, then the action for CMC change-control owner - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others - Owner and next date for CMC change-control owner in a safety team sitting on a new disproportionate signal